Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($0.15), $0.07 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $15.4 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.